Stay updated on Cardiol Therapeutics Press Releases
Sign up to get notified when there's something new on the Cardiol Therapeutics Press Releases page.
Latest updates to the Cardiol Therapeutics Press Releases page
- Check7 days agoChange DetectedThe left price widgets on the Investor Resources page updated from $1.08 and $1.45 to $1.04 and $1.41.SummaryDifference0.5%
- Check14 days agoChange DetectedAdded a new press release item: ARCHER Phase II study results published February 10, 2026. Updated stock price indicators to $1.08 NASDAQ:CRDL and $1.45 TSX:CRDL, replacing the previous values of $1.02 and $1.39.SummaryDifference2%
- Check21 days agoChange DetectedStock prices in the investor panel updated from $1.00 and $1.36 to $1.02 and $1.39 on the Press Releases page.SummaryDifference0.5%
- Check28 days agoChange DetectedA new press release announcing the closing of a bought deal financing for 14.85 million dollars dated January 23, 2026 was added to the Press Releases page, and an older ARCHER trial topline release from August 6, 2025 was removed. The page's stock price figures updated from $1.005 and $1.40 to $1.00 and $1.36.SummaryDifference1%
- Check35 days agoChange DetectedAdded a new press release announcing a $13.5 million bought‑deal financing and updated stock price figures ($1.06 and $1.465). Removed an older press release about the ARCHER trial database lock (July 22, 2025).SummaryDifference1%
- Check42 days agoChange DetectedA new press release entry Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis dated January 13, 2026 was added to the Press Releases page. Stock price figures were updated from $1.00 and $1.42 to $0.9599 and $1.34, and the older AGM press release was removed.SummaryDifference1%
Stay in the know with updates to Cardiol Therapeutics Press Releases
Enter your email address, and we'll notify you when there's something new on the Cardiol Therapeutics Press Releases page.